Moderna President, Stephen Hoge, M.D. and FORTUNE's Editor-in-Chief, Alyson Shontell, will discuss Moderna’s meteoric rise from R&D-focused startup to global commercial enterprise. The public witnessed the company’s decade-long investment in messenger RNA (mRNA) pay off, as it led to development of one of the world’s first COVID-19 vaccines during the worldwide health crisis. For entrepreneurs and leaders grappling with challenges of scale, Hoge will discuss the implications and lessons learned for Moderna’s business, its people and culture, the biotech industry, and the future of medicine.